Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 7.0 points at 17,678 as of Thursday, Nov 20, 2014, 10:36 a.m. ET. During this time, 55.3 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 329.3 million. The NYSE advances/declines ratio sits at 1,822 issues advancing vs. 1,086 declining with 185 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Friday, November 21, 2014 is the ex-dividend date for Dow component Johnson & Johnson (NYSE: JNJ). Owners of shares as of market close today will be eligible for a dividend of 70 cents per share. At a price of $107.88 as of 10:36 a.m. ET, the dividend yield is 2.6% compared to the average Dow component yield of 2.5%.

The average volume for Johnson & Johnson has been 7.5 million shares per day over the past 30 days. Johnson & Johnson has a market cap of $304.63 billion and is part of the health care sector and drugs industry. Shares are up 18.8% year-to-date as of Wednesday's close.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 18, equal to the average drugs industry P/E ratio.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again